Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $69 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 64.5× Travere Therapeutics Inc. Common Stock's market cap, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is more actively traded (10,680,748 versus 2,060,842). Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 132 Days on average.
| TVTX | VEA | |
|---|---|---|
Market Cap | $5.02B | $323.80B |
Volume | 2,060,842 | 10,680,748 |
Sector | Health | — |
52-Week High | $67.52 | $73.79 |
52-Week Low | $26.79 | $58.90 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $5.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
VEA trades at $70.06, up 0.16% today, with a bearish technical signal driven by moving averages. The ETF offers exposure to developed markets outside the U.S. with a low 0.03% expense ratio and a dividend yield. Recent institutional activity is mixed, with some firms increasing stakes while others reduced positions.
The outlook is neutral to cautious given bearish technicals and mixed sentiment. Key opportunities include cost efficiency and diversification benefits, but risks involve global market volatility and currency fluctuations. Investors should weigh the ETF's low-cost structure against broader economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
